Clinical Trial

Mobile Lung Cancer Screening

Study acronym: MobILYAD
Recruiting
View on ClinicalTrials.gov →
Summary
Lung cancer screening using low-dose CT (LDCT) has been shown to reduce mortality in high-risk populations. In 2022, the French National Cancer Institute (INCa) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current smokers or those who quit less than 15 years ago. A national pilot program (IMPULSION) will be launched in 2025. Lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. Mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (UK, Brazil, USA). In France, this approach has been used for breast cancer screening via mobile mammography units. The MobILYAD project aims to compare two screening modalities- a mobile demedicalized unit (CT-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-03; most recent amendment 2025-09-02.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT07015151
Lead Sponsor Hospices Civils de Lyon
Conditions Lung Cancer Prevention
Enrollment 4,312 participants
Start Date 2025-06-12
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-09